Greenyn Biotechnology Co (ROCO:6846) Total Liabilities : NT$469.8 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Total Liabilities?

Greenyn Biotechnology Co's Total Liabilities for the quarter that ended in Mar. 2024 was NT$469.8 Mil.

Greenyn Biotechnology Co's quarterly Total Liabilities increased from Sep. 2023 (NT$257.69 Mil) to Dec. 2023 (NT$364.48 Mil) and increased from Dec. 2023 (NT$364.48 Mil) to Mar. 2024 (NT$469.82 Mil).

Greenyn Biotechnology Co's annual Total Liabilities increased from Dec. 2021 (NT$231.09 Mil) to Dec. 2022 (NT$272.80 Mil) and increased from Dec. 2022 (NT$272.80 Mil) to Dec. 2023 (NT$364.48 Mil).

Greenyn Biotechnology Co Total Liabilities Historical Data

The historical data trend for Greenyn Biotechnology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Total Liabilities Chart

Greenyn Biotechnology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

244.70

262.88

231.09

272.80

364.48

Greenyn Biotechnology Co Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial										369.55	278.64	257.69	364.48	469.82

Greenyn Biotechnology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Greenyn Biotechnology Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	306.041	+	(55.917	+	2.518
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	364.5

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1161.387	-	796.911
	=	364.5

Greenyn Biotechnology Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	412.63	+	(53.69	+	3.498
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	469.8

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1215.408	-	745.59
	=	469.8

Greenyn Biotechnology Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenyn Biotechnology Co (ROCO:6846) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5th Floor, No 43 Keya Road, Daya District, Taichung, TWN

Website

https://www.greenynbio.com

Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines